GSK plc
CIK 1131399
13F filing for Q2 2026・No. 3,507
- Holdings
- US$602.22M
- Quarter change
- +US$3.07M
- Entries
- 13
- Net bought (estimate)
- US$0
The quarter change is the holdings' value against the quarter before, price moves included — not what was bought or sold; each institution's page estimates that.
Net bought (estimate)
Each stock's change in shares at the quarter-end price, added up: a new position counts as bought, one sold out as sold, shares held long only. Splits are compared split-adjusted; corporate actions under a new CUSIP are not estimated. An estimate from the filings, not actual trades.
- New 0
- Sold out 0
- Cut 0
- Added 0
- Corporate actions 0
- Unchanged 13
Largest holdings
13 stocks worth US$602.22M, options and bonds left out.
| Stock | This quarter | Shares | Value | Weight |
|---|---|---|---|---|
| CRSPCRISPR THERAPEUTICS AGNAMEN AKT | Unchanged | 3,220,627 | US$175.65M | 29.17% |
| 9666679DWAVE LIFE SCIENCES LTDSHS | Unchanged | 18,245,691 | US$106.01M | 17.60% |
| VIR BIOTECHNOLOGY INCCOM | Unchanged | 8,550,954 | US$87.13M | 14.47% |
| BNTXBIONTECH SESPONSORED ADS | Unchanged | 889,824 | US$82.8M | 13.75% |
| IDEAYA BIOSCIENCES INCCOM | Unchanged | 1,333,333 | US$49.69M | 8.25% |
| CYTOKINETICS INCCOM NEW | Unchanged | 340,434 | US$29M | 4.82% |
| LYELL IMMUNOPHARMA INCCOM NEW | Unchanged | 1,512,659 | US$21.25M | 3.53% |
| SPERO THERAPEUTICS INCCOM | Unchanged | 9,190,606 | US$20.31M | 3.37% |
| NKARTA INCCOM | Unchanged | 3,150,732 | US$8.92M | 1.48% |
| FULCRUM THERAPEUTICS INCCOM | Unchanged | 1,785,714 | US$6.54M | 1.09% |
Sign in (free) to see its 13 largest holdings and its trades. Sign in
Filings
The quarter's original 13F filings (SEC).
- 13F-HRFiled August 13, 2026SEC ↗
13F covers long positions in US-listed securities only; the data is SEC's, filed within 45 days of the quarter's end.